sirukumab
mAbexperimental
Sirukumab is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It acts against the proinflammatory cytokine Interleukin 6 (IL-6). — Wikipedia
Clinical trial activity
16 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
12
Phase 3
7
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT01702740)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-6INHIBITOR
IL6 inhibitor
It binds to soluble IL-6 and inhibits IL-6-mediated signal transducers and activation of transcription-3 phosphorylation (STAT-3).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSirukumab ↗
- ChEMBLCHEMBL1743071 ↗
Also known as
- cnto 136
- cnto-136
- sirukumab
- sirukumab
- sirukumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04380961 | Phase 2 | Apr 24, 2020 | Janssen Pharmaceutica NV |
| NCT02899026 | Phase 3 | Mar 15, 2018 | GlaxoSmithKline |
| NCT02794519 | Phase 2 | Sep 1, 2016 | GlaxoSmithKline |
| NCT02531633 | Phase 3 | Oct 16, 2015 | GlaxoSmithKline |
| NCT02473289 | Phase 2 | Jul 23, 2015 | Johnson and Johnson |
| NCT02019472 | Phase 3 | Apr 1, 2014 | GlaxoSmithKline, Johnson and Johnson |
| NCT02079545 | Phase 1 | Mar 1, 2014 | GlaxoSmithKline, Johnson and Johnson |
| NCT01856309 | Phase 3 | Aug 1, 2013 | GlaxoSmithKline, Johnson and Johnson |
| NCT01689532 | Phase 3 | Nov 1, 2012 | GlaxoSmithKline, Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01636557 | Phase 1 | Oct 11, 2012 | Johnson and Johnson |
| NCT01604343 | Phase 3 | Aug 1, 2012 | GlaxoSmithKline, Johnson and Johnson |
| NCT01606761 | Phase 3 | Aug 1, 2012 | GlaxoSmithKline, Johnson and Johnson |
| NCT01273389 | Phase 2 | Aug 1, 2011 | Johnson and Johnson |
| NCT00844909 | Phase 1 | Jan 1, 2009 | Centocor |
| NCT00718718 | Phase 2 | Aug 1, 2008 | Centocor |
| NCT01702740 | Phase 1 | Mar 1, 2007 | Centocor |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 9 | 3 | 3 | 2012 |
| Johnson and Johnson | For profit | 9 | 9 | 3 | 2011 |
| Centocor | For profit | 3 | 3 | 2 | 2007 |
| Janssen Pharmaceutica NV | For profit | 2 | 1 | 2 | 2012 |
4 organizations
Page 1 / 1